Pharma

The global pharmaceutical landscape is witnessing a seismic shift, and Indian drugmakers are positioned at its epicentre. As the US biosimilars market prepares to quadruple from $22.6 billion in 2025 to a staggering $90 billion by 2034, a revolutionary FDA draft guideline has thrown open the gates for Indian manufacturers. By potentially halving development costs […]

Western sanctions were meant to isolate Russia—instead, they’ve opened the door for India. While European and American pharmaceutical companies retreat from the Russian market under pressure from their governments, Indian manufacturers are advancing, negotiating joint ventures, planning production facilities, and positioning themselves as the primary suppliers to a nation desperate for pharmaceutical self-sufficiency. Russia already